Mycosis fungoides primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
There are no established measures for the primary prevention of [disease name].
There are no established measures for the primary prevention of mycosis fungoides.
 
OR
 
There are no available vaccines against [disease name].
 
OR
 
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
 
OR
 
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].


==Primary Prevention==
==Primary Prevention==
There are no established measures for the primary prevention of [disease name].
There are no established measures for the primary prevention of mycosis fungoides.
 
OR
 
There are no available vaccines against [disease name].
 
OR
 
Effective measures for the primary prevention of [disease name] include:
*[Measure1]
*[Measure2]
*[Measure3]
 
OR
 
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
*[Strategy 1]
*[Strategy 2]
*[Strategy 3]


==References==
==References==

Revision as of 20:30, 19 December 2018

Cutaneous T cell lymphoma Microchapters

Home

Patient Information

Overview

Classification

Mycosis fungoides
Sezary syndrome

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the primary prevention of mycosis fungoides.

Primary Prevention

There are no established measures for the primary prevention of mycosis fungoides.

References

Template:WH Template:WS